Everest Medicines (STU:6HN) Accounts Payable & Accrued Expense : €32.55 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Everest Medicines Accounts Payable & Accrued Expense?

Everest Medicines's quarterly accounts payable & accrued expense declined from Dec. 2023 (€31.92 Mil) to Jun. 2024 (€25.23 Mil) but then increased from Jun. 2024 (€25.23 Mil) to Dec. 2024 (€32.55 Mil).

Everest Medicines's annual accounts payable & accrued expense declined from Dec. 2022 (€57.63 Mil) to Dec. 2023 (€31.92 Mil) but then increased from Dec. 2023 (€31.92 Mil) to Dec. 2024 (€32.55 Mil).

Everest Medicines Accounts Payable & Accrued Expense Historical Data

The historical data trend for Everest Medicines's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Accounts Payable & Accrued Expense Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

16.35

26.58

57.63

31.92

32.55

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial							57.63	18.78	31.92	25.23	32.55

Everest Medicines Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Everest Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (STU:6HN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

01952:Hong Kong 6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China.

Everest Medicines Headlines

No Headlines